Brain and Spinal Cord Tumor Care
The University of Chicago Brain Tumor Center is at the forefront of sophisticated care for primary and metastatic tumors of the central nervous system (CNS), including brain and spinal cord tumors. Our multidisciplinary team engages neuro-oncologists, neurosurgeons, radiation oncologists and hematologist/oncologists in the integrated planning and delivery of individualized patient care, including:
- Definitive diagnostic assessments using the latest technology and minimally invasive techniques to pinpoint even the most difficult-to-detect tumors
- A range of comprehensive treatment options for benign and malignant CNS tumors
- Multidisciplinary management of metastatic cancer by experts in the University of Chicago CNS Metastases Center
- Specialized expertise in hemangioblastomas of the brain and spine associated with von Hippel-Lindau disease
Read more about our team of experts.
Leading the Advancement of CNS Tumor Treatment
At the Brain Tumor Center, treatment strategies are guided by innovative research conducted here at the University of Chicago. Our experts are dedicated to building a foundation for future advancements in the treatment of brain and spinal cord tumors.
In our basic science program, researchers investigate underlying mechanisms involved in the development, survival, and dissemination of tumors in the nervous system. Through high-profile, collaborative initiatives with the University of Chicago Comprehensive Cancer Center, our experts are poised to substantially advance the treatment and prevention of CNS metastases. Such basic and translational science endeavors are supported by numerous grants, including the $90 million grant supporting the Ludwig Center for Metastases Research.
Access to Innovative Clinical Trials
University of Chicago experts are also conducting robust clinical research focused on CNS tumors. Our Comprehensive Cancer Center offers access to the entire range of Phase I, II, and III trials supported by the National Institutes of Health (NIH) for newly diagnosed and progressive gliomas, as well as brain metastases. We are Chicago’s only National Cancer Institute (NCI) sponsored Lead Academic Participating Site (LAPS), and one of only 30 sites nationwide.
In addition to national trials supported by the NIH, our portfolio includes industry and investigator sponsored clinical trials. These studies involve a range of treatment modalities, including surgery, radiation, chemotherapy, targeted drugs, immunotherapy and vaccines.